BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
CLSA maintains buy on Lupin
The brokerage expects growth momentum in US generics to sustain and believes there is further room for margin improvement. Margin profile of the company to improve as product mix strengthen, adds CLSA.